The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Cbeyond met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue dropped slightly and GAAP earnings per share grew. The profit was a surprise, as analysts had predicted a loss.
Margins grew across the board.
Cbeyond notched revenue of $121.5 million. The 10 analysts polled by S&P Capital IQ expected revenue of $121.7 million on the same basis. GAAP reported sales were 0.8% lower than the prior-year quarter's $122.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.06. The nine earnings estimates compiled by S&P Capital IQ averaged -$0.02 per share. GAAP EPS were $0.06 for Q3 compared to -$0.04 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 68.2%, 120 basis points better than the prior-year quarter. Operating margin was 3.3%, 400 basis points better than the prior-year quarter. Net margin was 1.6%, 250 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $120.7 million. On the bottom line, the average EPS estimate is -$0.05.
Next year's average estimate for revenue is $490.2 million. The average EPS estimate is $0.00.
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 106 members out of 140 rating the stock outperform, and 34 members rating it underperform. Among 41 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 26 give Cbeyond a green thumbs-up, and 15 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Cbeyond is hold, with an average price target of $9.17.
- Add Cbeyond to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why Sarepta Therapeutics, Cbeyond, and Advanced Micro Devices Are Today's 3 Best Stocks
The S&P 500 makes it a perfect five-for-five as Sarepta Therapeutics, Cbeyond, and Advanced Micro Devices all skyrocket higher.
Why Cbeyond Inc. Shares Skyrocketed
Is this meaningful or just another movement?
Cbeyond Beats on EPS But GAAP Results Lag
Just the facts, Fool.